OSE Immuno - Expands collaboration with Boehringer
• OSE Immuno and Boehringer Ingelheim announced an expansion of their partnership with two new projects. First, the development of the anti-SIRPα immuno-oncology compounds for which they have an existing collaboration will now also be pursued in cardiovascularrenal-metabolic diseases. Second, a new preclinical program will be launched to develop immune-cell activating treatments based on OSE's cis-targeting anti-PD1/cytokine platform via an asset acquisition• EUR 13.5m upfront payment to be received and a potential near-term milestone of EUR 17.5 million for the purchase of a novel, cis-targeting anti-PD-1/cytokine asset in preclinical stage• Positive news for the company, which further underlines the valueOse Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.